US30052C1071
© BusinessWire
09.01.2026
EOLS
LISTED
NASDAQ
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
News Preview
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2025. The preliminary unaudited results described in this press release are based on the most current information available...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company’s common stock to 13 newly hire...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
EOLS
LISTED
NASDAQ
Evolus Reports Third Quarter 2025 Financial Results
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2025.
“Our third quarter results reflect double-digit growth despite the current market environment. Our continued above market performance an...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
28.10.2025
EOLS
LISTED
NASDAQ
Evolus to Participate in 2025 Stifel Healthcare Conference
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Stifel Healthcare Conference.
The fireside chat will take place on Tuesday, November 11, 2025, at 11...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
22.10.2025
EOLS
LISTED
NASDAQ
Evolus to Report Third Quarter Financial Results on November 5, 2025
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discus...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase an aggregate of 24,931 shares of Evolus and an aggregate of 31,116 restricted stock units (RSUs) of the company’s common stock to 9 newly hired...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
EOLS
LISTED
NASDAQ
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
News Preview
Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.
MIAMI BEACH, Fla., Sept. 22,...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2025
EOLS
LISTED
NASDAQ
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (RSUs) of the company’s common stock to 6 newly hired...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
EOLS
LISTED
NASDAQ
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025.
Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and privat...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
EOLS
LISTED
NASDAQ
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.
“Achieving positive topline results in our mid-fa...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
EOLS
LISTED
NASDAQ
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
EOLS
LISTED
NASDAQ
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau® (prabotulinumtoxinA-xvfs), B...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
22.07.2025
EOLS
LISTED
NASDAQ
Evolus to Report Second Quarter Financial Results on August 5, 2025
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss t...
Themefolio
Profiler
Peergroup
© BusinessWire
11.07.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company’s common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation co...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
EOLS
LISTED
NASDAQ
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinum toxin type A) in France.
Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of mo...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company’s common stock to 17 newly hired no...
Themefolio
Profiler
Peergroup
© BusinessWire
10.06.2025
EOLS
LISTED
NASDAQ
Evolysse™ Recognized in 2025 Shape Skin Awards
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards:
Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line
Best Membership Treatment Mo...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
EOLS
LISTED
NASDAQ
Evolus Announces Departure of its Chief Financial Officer
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver’s resignation is not...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
EOLS
LISTED
NASDAQ
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of the U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusing on advances in aesthetic medicine and surg...
Themefolio
Profiler
Peergroup
© BusinessWire
16.05.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of non-qualified stock options to purchase an aggregate of 12,706 shares of Evolus and an aggregate of 40,576 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
EOLS
LISTED
NASDAQ
Evolus Reports First Quarter 2025 Results
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2025.
“Coming off a record year, we enter 2025 with strong momentum,” said David Moatazedi, President and Chief Executive Officer of Evolus. “In o...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
EOLS
LISTED
NASDAQ
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP.
Highli...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
EOLS
LISTED
NASDAQ
Evolus to Report First Quarter Financial Results on May 7, 2025
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss thes...
Themefolio
Profiler
Peergroup
© BusinessWire
18.04.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company’s common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
EOLS
LISTED
NASDAQ
Evolus Announces Commercial Launch of Evolysse™
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th.
To support the introduction, Evolu...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
EOLS
LISTED
NASDAQ
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of Evolysse™. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
EOLS
LISTED
NASDAQ
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference.
The fireside chat will take place on Tuesday, April 8, 2025, at 12:45...
Themefolio
Profiler
Peergroup
© BusinessWire
21.03.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company’s common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
EOLS
LISTED
NASDAQ
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024.
“We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth conse...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
EOLS
LISTED
NASDAQ
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in fireside chats and investor meetings at upcoming investor conferences in Miami, FL:
The Leerink Partners Global Biopharma Conference, the fireside chat will take place...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
EOLS
LISTED
NASDAQ
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025.
As part of the event, David Moatazedi, President and...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
EOLS
LISTED
NASDAQ
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast t...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
EOLS
LISTED
NASDAQ
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection. These approvals mark Evolus’ entry int...
Themefolio
Profiler
Peergroup
© BusinessWire
08.02.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 26,897 shares of Evolus and an aggregate of 99,826 restricted stock units (RSUs) of the company’s common stock to 34 newly hired non-execut...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
EOLS
LISTED
NASDAQ
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
News Preview
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The preliminary unaudited results described in this press release are based on the most current information available...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the company’s common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to purchase an aggregate of 9,872 shares of Evolus and an aggregate of 16,596 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
EOLS
LISTED
NASDAQ
Evolus Reports Third Quarter 2024 Results
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
“Our third quarter results underscore the momentum we’ve been building throughout the year,” said David Moata...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
EOLS
LISTED
NASDAQ
Evolus to Participate in Stifel 2024 Healthcare Conference
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET.
The presentation can be accessed on the Investor Relations page of the Evolus websi...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
EOLS
LISTED
NASDAQ
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced “esteem”), branded as Evolysse™ in the U.S. mar...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
EOLS
LISTED
NASDAQ
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program.
“The achievement of these milestones underscores the...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
EOLS
LISTED
NASDAQ
Evolus to Report Third Quarter Financial Results on November 6, 2024
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss...
Themefolio
Profiler
Peergroup
© BusinessWire
12.10.2024
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and an aggregate of 31,049 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-execut...
Themefolio
Profiler
Peergroup
© BusinessWire
28.09.2024
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company’s common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee...
Themefolio
Profiler
Peergroup
© BusinessWire
06.09.2024
EOLS
LISTED
NASDAQ
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasdaq closing bell on Friday, September 13, 2024.
The Nasdaq closing bell ceremony is a time-honored tradition, serving as a platform for companies to celebrate achievements and milestones. T...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
EOLS
LISTED
NASDAQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-executive employees of the company (the “July Grants”). The Company also is reporting...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
